Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $116.30 Average Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has received an average rating of “Buy” from the twenty-two ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $116.30.

A number of equities research analysts have commented on KYMR shares. Morgan Stanley raised their price target on Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Guggenheim began coverage on Kymera Therapeutics in a research report on Monday, November 3rd. They set a “buy” rating and a $90.00 target price for the company. B. Riley lifted their target price on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group increased their price objective on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday, December 9th.

Insider Activity

In related news, Director Bruce Booth sold 229,809 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total transaction of $21,080,379.57. Following the completion of the transaction, the director directly owned 686,477 shares of the company’s stock, valued at approximately $62,970,535.21. This trade represents a 25.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the completion of the sale, the insider owned 109,992 shares in the company, valued at approximately $6,755,708.64. The trade was a 35.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 518,585 shares of company stock valued at $43,749,999 in the last quarter. Company insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Holocene Advisors LP purchased a new position in Kymera Therapeutics during the 3rd quarter valued at $47,563,000. Commodore Capital LP bought a new stake in shares of Kymera Therapeutics during the second quarter worth $32,730,000. Alyeska Investment Group L.P. boosted its stake in shares of Kymera Therapeutics by 1,130.2% during the third quarter. Alyeska Investment Group L.P. now owns 615,091 shares of the company’s stock valued at $34,814,000 after purchasing an additional 565,091 shares during the period. Federated Hermes Inc. purchased a new stake in shares of Kymera Therapeutics during the third quarter valued at $31,622,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the last quarter.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $74.77 on Thursday. The company has a market capitalization of $5.38 billion, a P/E ratio of -20.83 and a beta of 2.21. Kymera Therapeutics has a 1-year low of $19.44 and a 1-year high of $103.00. The firm’s 50 day simple moving average is $72.92 and its two-hundred day simple moving average is $56.99.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm had revenue of $2.76 million for the quarter, compared to the consensus estimate of $23.15 million. On average, sell-side analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.